

US Family Health Plan
 Prior Authorization Request Form for
Androgel, testosterone 1% and 1.62% MDP, gel and gel packets, 2% testosterone solution MDP, 1% testosterone gel in unit-dose tubes (Testim, Vogelxo, generics)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:
Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

Clinical documentation including labs may be required.

Initial therapy approves for 1 year, renewal approves indefinitely. For renewal of therapy, an initial Tricare prior authorization approval is required.

Step 1 Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID #: _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

Step 2 Please complete the clinical assessment:

1. Will the requested medication be used to enhance athletic performance?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 2
2. Will the requested medication be used concomitantly with other testosterone products?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 3
3. Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for the requested medication.	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No Proceed to question 6
4. Has the patient had a positive response to therapy?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No STOP Coverage not approved
5. Do the benefits of continued therapy outweigh the risks?	<input type="checkbox"/> Yes Sign and date on page 3	<input type="checkbox"/> No STOP Coverage not approved

6. What is the indication or diagnosis?	<input type="checkbox"/> Hypogonadism - Proceed to question 7 <input type="checkbox"/> Female-to-male gender-affirming hormone therapy in a natal female patient (assigned female at birth) - Proceed to question 14 <input type="checkbox"/> Other - Proceed to question 22	
7. Is the patient a male who is 18 years of age or older?	<input type="checkbox"/> Yes Proceed to question 8	<input type="checkbox"/> No STOP Coverage not approved
8. Does the patient have a confirmed diagnosis of hypogonadism as evidenced by morning total serum testosterone levels below 300 ng/dL taken on at least two separate occasions?	<input type="checkbox"/> Yes Proceed to question 10	<input type="checkbox"/> No Proceed to question 9
9. Is testosterone being prescribed by an endocrinologist or urologist who has made the diagnosis of hypogonadism based on unequivocally and consistently low serum total testosterone or free testosterone levels?	<input type="checkbox"/> Yes Proceed to question 10	<input type="checkbox"/> No STOP Coverage not approved
10. Is the patient experiencing signs and symptoms associated with hypogonadism?	<input type="checkbox"/> Yes Proceed to question 11	<input type="checkbox"/> No STOP Coverage not approved
11. Has the provider investigated the etiology of the low testosterone levels?	<input type="checkbox"/> Yes Proceed to question 12	<input type="checkbox"/> No STOP Coverage not approved
12. Has the provider assessed the risks versus benefits of initiating testosterone therapy in this patient?	<input type="checkbox"/> Yes Proceed to question 13	<input type="checkbox"/> No STOP Coverage not approved
13. Does the provider acknowledge that testosterone therapy is clinically appropriate and needed?	<input type="checkbox"/> Yes Proceed to question 23	<input type="checkbox"/> No STOP Coverage not approved
14. Is the patient greater than or equal to 14 years of age?	<input type="checkbox"/> Yes Proceed to question 15	<input type="checkbox"/> No STOP Coverage not approved
15. Does the patient have a diagnosis of gender dysphoria made by a TRICARE-authorized mental health provider according to the most current edition of the DSM?	<input type="checkbox"/> Yes Proceed to question 16	<input type="checkbox"/> No STOP Coverage not approved

US Family Health Plan
 Prior Authorization Request Form for
 Androgel, testosterone 1% and 1.62% MDP, gel and gel packets, 2% testosterone
 solution MDP, 1% testosterone gel in unit-dose tubes (Testim, Vogelxo, generics)

16. Is the requested medication being prescribed by an endocrinologist or a physician who specializes in the treatment of transgender patients?	<input type="checkbox"/> Yes Proceed to question 17	<input type="checkbox"/> No STOP Coverage not approved
17. Is the patient an adult, or an adolescent with sufficient mental capacity to give informed consent for this partially irreversible treatment?	<input type="checkbox"/> Yes Proceed to question 18	<input type="checkbox"/> No STOP Coverage not approved
18. Has the patient experienced puberty to at least Tanner stage 2?	<input type="checkbox"/> Yes Proceed to question 19	<input type="checkbox"/> No STOP Coverage not approved
19. Is the patient a biological female of childbearing potential?	<input type="checkbox"/> Yes Proceed to question 20	<input type="checkbox"/> No Proceed to question 21
20. Is the patient pregnant or breastfeeding?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 21
21. Does the patient have a psychiatric comorbidity that would confound a diagnosis of gender dysphoria or interfere with treatment (for example: unresolved body dysmorphic disorder; schizophrenia or other psychotic disorders that have not been stabilized with treatment)?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 23
22. Document the requested indication and rationale for use.	<hr style="width: 80%; margin: 0 auto;"/> Proceed to question 23	
23. What is the requested medication?	<input type="checkbox"/> testosterone 1% gel (for example, generic Androgel, generic Testim, etc.) - Sign and date below <input type="checkbox"/> testosterone 1.62% gel (for example, generic Androgel, etc.) - Sign and date below <input type="checkbox"/> testosterone 2% solution (for example, generic Axiron, etc.) - Sign and date below <input type="checkbox"/> Other (for example Androderm, Fortesta (2% testosterone gel multi-dose pump (MDP)), Natesto, brand Testosterone 1% gel packet, brand Vogelxo) - Proceed to question 24	
24. Has the patient tried and failed a 3-month trial of one of the following medications: testosterone 1% gel (for example, generic Androgel, generic Testim, etc.), 1.62% gel (for example, generic Androgel, etc.), or 2% solution (for example, generic Axiron, etc.)?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Proceed to question 25

US Family Health Plan
Prior Authorization Request Form for
Androgel, testosterone 1% and 1.62% MDP, gel and gel packets, 2% testosterone
solution MDP, 1% testosterone gel in unit-dose tubes (Testim, Vogelxo, generics)

25. Has the patient experienced a clinically significant adverse reaction to one of the following medications: testosterone 1% gel (for example, generic Androgel, generic Testim, etc.), 1.62% gel (for example, generic Androgel, etc.), or 2% solution (for example, generic Axiron, etc.)?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Proceed to question 26
26. Has the patient had a contraindication or relative contraindication to one of the following medications: testosterone 1% gel (for example, generic Androgel, generic Testim, etc.), 1.62% gel (for example, generic Androgel, etc.), or 2% solution (for example, generic Axiron, etc.)?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No STOP Coverage not approved

Step I certify the above is true to the best of my knowledge. Please sign and date:

3

Prescriber Signature

Date

[29 May 2024]